JP2012522513A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522513A5
JP2012522513A5 JP2012503682A JP2012503682A JP2012522513A5 JP 2012522513 A5 JP2012522513 A5 JP 2012522513A5 JP 2012503682 A JP2012503682 A JP 2012503682A JP 2012503682 A JP2012503682 A JP 2012503682A JP 2012522513 A5 JP2012522513 A5 JP 2012522513A5
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
immunoconjugate
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012503682A
Other languages
English (en)
Japanese (ja)
Other versions
JP6099976B2 (ja
JP2012522513A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/029521 external-priority patent/WO2010114940A1/en
Publication of JP2012522513A publication Critical patent/JP2012522513A/ja
Publication of JP2012522513A5 publication Critical patent/JP2012522513A5/ja
Application granted granted Critical
Publication of JP6099976B2 publication Critical patent/JP6099976B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2012503682A 2009-04-01 2010-03-31 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法 Expired - Fee Related JP6099976B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21175409P 2009-04-01 2009-04-01
US61/211,754 2009-04-01
US16621409P 2009-04-02 2009-04-02
US61/166,214 2009-04-02
PCT/US2010/029521 WO2010114940A1 (en) 2009-04-01 2010-03-31 Anti-fcrh5 antibodies and immunoconjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015168182A Division JP2016028052A (ja) 2009-04-01 2015-08-27 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法

Publications (3)

Publication Number Publication Date
JP2012522513A JP2012522513A (ja) 2012-09-27
JP2012522513A5 true JP2012522513A5 (enExample) 2013-05-16
JP6099976B2 JP6099976B2 (ja) 2017-03-29

Family

ID=42236394

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503682A Expired - Fee Related JP6099976B2 (ja) 2009-04-01 2010-03-31 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法
JP2015168182A Pending JP2016028052A (ja) 2009-04-01 2015-08-27 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015168182A Pending JP2016028052A (ja) 2009-04-01 2015-08-27 抗ＦｃＲＨ５抗体および免疫接合体ならびに使用方法

Country Status (18)

Country Link
US (2) US8362213B2 (enExample)
EP (1) EP2414395A1 (enExample)
JP (2) JP6099976B2 (enExample)
KR (1) KR20120003478A (enExample)
CN (1) CN102369218B (enExample)
AR (1) AR076030A1 (enExample)
AU (1) AU2010232682A1 (enExample)
BR (1) BRPI1012560A2 (enExample)
CA (1) CA2756988A1 (enExample)
CL (1) CL2011002418A1 (enExample)
IL (1) IL215404A0 (enExample)
MX (1) MX2011010265A (enExample)
PE (1) PE20120877A1 (enExample)
RU (2) RU2016110891A (enExample)
SG (1) SG174930A1 (enExample)
TW (1) TW201039846A (enExample)
WO (1) WO2010114940A1 (enExample)
ZA (1) ZA201107128B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010264A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
DK2714684T3 (en) * 2011-05-27 2018-11-26 Ambrx Inc COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
KR102626525B1 (ko) * 2013-02-08 2024-01-19 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
MX364459B (es) 2013-03-29 2019-04-26 Sumitomo Dainippon Pharma Co Ltd Vacuna de conjugado de péptido-antígeno de wt1.
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
AR096687A1 (es) * 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
JP6208864B2 (ja) 2013-06-24 2017-10-04 エービーエルバイオ 安定性が改善された抗体−薬物結合体およびこれの用途
BR112016007736B1 (pt) 2013-10-11 2022-09-27 Mersana Therapeutics, Inc Armação polimérica, e, composição farmacêutica
IL245009B (en) 2013-10-11 2022-08-01 Asana Biosciences Llc Protein-polymer-drug conjugates
CA3131724A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3191520B1 (en) 2014-09-12 2020-01-01 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
AU2015339012B2 (en) * 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
CN109072199B (zh) 2014-12-05 2022-10-28 纪念斯隆-凯特琳癌症中心 靶向Fc受体样5的嵌合抗原受体及其用途
AR104987A1 (es) * 2015-06-15 2017-08-30 Genentech Inc Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
KR20250021639A (ko) 2015-06-16 2025-02-13 제넨테크, 인크. FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
CA3007115A1 (en) * 2015-12-04 2017-06-08 Memorial Sloan-Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
JPWO2017188346A1 (ja) * 2016-04-27 2019-02-28 国立大学法人 東京大学 マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法
KR20190039085A (ko) * 2016-06-17 2019-04-10 마젠타 테라퓨틱스 인코포레이티드 세포의 고갈을 위한 조성물 및 방법
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018237335A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. IMMUNOCONJUGUATED ROR1 ANTIBODIES
WO2019020745A1 (en) 2017-07-28 2019-01-31 F. Hoffmann-La Roche Ag Bispecific antibody formulation
FI3666787T3 (fi) 2017-08-10 2024-03-15 Sumitomo Pharma Co Ltd Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja
US12018093B2 (en) 2017-08-10 2024-06-25 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
US10766613B2 (en) * 2017-11-28 2020-09-08 Textron Innovations Inc. System and method for rotorcraft-weight-on-wheels flight state transition control
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
KR20200118065A (ko) 2018-02-08 2020-10-14 제넨테크, 인크. 이중특이적 항원-결합 분자 및 이의 사용 방법
WO2019173503A2 (en) 2018-03-06 2019-09-12 Imcare Biotech, Llc Serine protease inhibitor kazal (spik) compositions and methods
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020023106A1 (en) * 2018-07-25 2020-01-30 Northeastern University Selectivity screening for antimicrobial compounds
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7560255B2 (ja) * 2019-02-13 2024-10-02 住友ファーマ株式会社 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
JP7479302B2 (ja) * 2019-02-13 2024-05-08 住友ファーマ株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
CA3127312A1 (en) 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
CN113329792B (zh) 2019-02-15 2024-06-28 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
WO2021007338A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021050217A1 (en) 2019-09-11 2021-03-18 Imcare Biotech, Llc. Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
JP2023507120A (ja) 2019-12-18 2023-02-21 テネオフォー， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
AU2020406350A1 (en) 2019-12-20 2022-08-11 Novartis Ag Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
MX2024005106A (es) 2021-11-03 2024-07-02 Affimed Gmbh Ligandos biespecificos de cd16a.
CA3247428A1 (en) * 2022-04-13 2023-10-19 Hoffmann La Roche Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024102948A1 (en) * 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用
WO2025235357A1 (en) 2024-05-06 2025-11-13 Rondo Therapeutics, Inc. Bispecific antibodies that bind to cd28 and nectin-4

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1995009864A1 (en) 1993-10-01 1995-04-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
US7074897B2 (en) 1997-06-16 2006-07-11 Genentech, Inc. Pro943 polypeptides
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
ES2568625T3 (es) * 1999-11-29 2016-05-03 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1423428B2 (en) * 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003043583A2 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
EP1696963A2 (en) 2003-12-24 2006-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
CN101103042A (zh) * 2005-01-12 2008-01-09 米德列斯公司 Irta-2抗体及其用途
SG155947A1 (en) * 2005-06-20 2009-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2008109533A2 (en) * 2007-03-02 2008-09-12 Medarex, Inc. Human antibodies that bind multiple irta family proteins, and uses thereof
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
MX2011010264A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.

Similar Documents

Publication Publication Date Title
JP2012522513A5 (enExample)
JP2012522512A5 (enExample)
JP2014139173A5 (enExample)
RU2011144119A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2011144141A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN106459200B (zh) 抗-egfr抗体及抗体药物偶联物
RU2483080C2 (ru) Антитела и иммуноконъюгаты и их применение
JP2019532056A5 (enExample)
JP2024075668A (ja) 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2016098233A5 (enExample)
JP2013056896A5 (enExample)
RU2694688C2 (ru) АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2016063817A5 (enExample)
JP2014509835A5 (enExample)
JP2018524349A5 (enExample)
HRP20161029T1 (hr) Protutijela anti-cd79b i imunokonjugati kao i postupci njihove uporabe
JP2015523961A5 (enExample)
JP2010523469A5 (enExample)
TW201406780A (zh) 抗－Ｌｙ６Ｅ抗體及免疫結合物及其使用方法
JP2017535246A5 (enExample)
HUE035171T2 (en) Combination therapy of Afucosylated CD 20 antibody with drug conjugate of CD79b antibody
JP7264831B2 (ja) 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用
US9381205B2 (en) Anti-EFNA4 antibody-drug conjugates
WO2024145398A1 (en) Antibody drug conjugates
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5